Rezolute is developing drug therapies to cure patients with metabolic diseases associated with chronic glucose imbalance. Both extreme low (hypoglycaemia) and high (hyperglycaemia) blood glucose levels cause disease. Rezolute is developing antibody-based therapies to treat patients with congenital hyperinsulinism (HI), diabetic macular edema and tumor HI. Their approach is to leverage their metabolic expertise to define disease pathways and create therapies that overcome the shortcomings of current standards of care. Rezolute’s lead program, RZ358, is in late-stage clinical trials for congenital HI.

Rezolute

Stock Quote and Chart


                    Rezolute to Participate in Upcoming Investor Conferences                

SEC Filings

 Rezolute's oral Eylea rival hits phase 2 goal, sending stock up 

 Rezolute appoints Daron Evans as CFO 

Handok and Genexine become largest stakeholder of Rezolute - KBR

Peninsula drug maker plots late-stage clinical trial after FDA lifts delay - The Business Journals

FDA authorises US trial of Rezolute’s drug candidate for congenital hyperinsulinism - Clinical Trials Arena

Governance

We're #hiring! Learn more about Rezolute and check out new opportunities to join our rapidly growing team: https://lnkd.in/ecAZetUr

 Handok Inc. director buys Rezolute shares worth $17 million 

Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St


		rss_feed Filing RSS
	


              Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia | NEJM
            

November is National Family Caregivers Month. We are caregivers, loved ones, and patients on a mission to develop therapies that make a difference. This month we also had the honor of attending the Congenital Hyperinsulinism International Family Conference in Liverpool and are grateful to have a community of patients, families, physicians, and researchers working to improve the lives of those living with HI. The role of caregiver can be filled with challenges and complexities, but also comes with many rewards and a profound impact on families and communities. Thank you to all caregivers for your hard work and commitment! 

#Caregiver #ResourcesForCaregivers #FamilyCaregiversMonth

Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com

State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World

After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trial - Fierce Biotech

 Rezolute Director Wladimir Hogenhuis Buys 4,815 Shares 

 Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying 

 Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day 

 Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying 

Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk - Fierce Biotech

 Rezolute receives Innovative Passport designation from MHRA for RZ358 

 Rezolute reports new KLKB1 inhibitors 

How an Israeli web service, a bong-like insulin device and a Bay Area deal led this Peninsula biotech to attack a childhood disease - The Business Journals

 FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism 

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market (NASDAQ:RZLT) - Seeking Alpha

Rezolute Grants 150,000-Share Inducement Award to New Supply Chain Executive - StockTitan

 Rezolute Shares Surge 50% On Study Meeting Primary Endpoints 

 Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer 


                    FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism                

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat

 Rezolute secures innovation passport designation from U.K. for RZ358 treating hypoglycemia 

Compassionate Use Program (CUP) Benefits & Strategies In Rare Disease - Clinical Leader

 Rezolute to Participate in the Jefferies Global Healthcare Conference 

 Rezolute stock rockets 50% on Phase 2 results for eye drug RZ402 

 Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) 

Page 10

Continuing Rare Disease Treatment With A Compassionate Use Program (CUP) - Clinical Leader

Investors & Media


                    Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update                

Page 64

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update - The Manila Times


                    FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study                

Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World

US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment - Reuters

Rezolute (RZLT) to Present at Guggenheim and Jefferies Healthcare Conferences - StockTitan

AAO 2024: Rezolute’s RZ-402 shows promising Phase IIa results in DME patients - Clinical Trials Arena

 Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert 

Analyst Coverage

 Rezolute gets FDA orphan drug designation for its hypoglycemia treatment 

Compassionate use programs play a crucial, yet often underappreciated, role in drug development; providing patients, particularly those with rare diseases, access to potentially life-saving therapies that may positively impact the trajectory of their health outcomes.
 
We're thrilled to publish, in partnership with WEP Clinical and Ana Paula Tediosi, this two-part series on compassionate use programs and the meaningful benefits in the development of a potential treatment for multiple forms of insulin receptor mediated hypoglycemia. https://bit.ly/4eXiL0O 

#clinicaltrials #clinicalresearch #raredisease #hypoglycemiaawarenessweek

 Rezolute files to sell 4.5M shares of common stock for holders 

 Rezolute dips 19%, prices $60M offering at $4 per share 

10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully - Yahoo Finance

Rezolute makes $130M to take disease drug into pivotal trial


                    Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement                

 Rezolute initiated with bullish view at Wedbush, here's why 


    			rss_feed News RSS
    		

Rezolute Advances Phase 3 Trials Despite $15.4M Loss; Maintains $117.8M Cash Position - StockTitan


                    Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism                

Email Alerts

Page 4

FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times

Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com

MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World

 Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment 

Page 9

Page 6

The Rezolute team had a great time at the 15th Annual German Family Conference hosted by Kongenitaler Hyperinsulinismus, eV last week in Berlin! We are grateful to the organizers for giving us the opportunity to meet with families, hear their stories, and share our novel approach to a potential treatment for #cHI.  

#sunRIZE #hyperinsulinism #hypoglycemia #raredisease

Page 2

We are thrilled to announce ersodetug has received Orphan Drug Designation for the treatment of hypoglycemia due to tumor hyperinsulinism (HI). This important recognition allows us to continue developing a potential universal treatment for hypoglycemia caused by all forms of HI. Read more: https://bit.ly/4il4xJW

Happy New Year from #Rezolute! 🎆 Here's a look at some of our 2024 milestones. We will continue to transform care for patients with rare diseases. Thank you for being a part of our journey!
#Rezolute #Healthcare #HappyNewYear2025

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat

 Rezolute’s oral diabetic macular edema drug hits phase II goal 

Page 1

As #HypoglycemiaAwarenessWeek comes to a close, Rezolute would like to shine a spotlight on the outstanding work our partner patient advocacies do each and every day to support patients and families living with #CongenitalHyperinsulinism. 

congenitalhi.org
hyperinsulinism.co.uk
https://lnkd.in/e3Ev92za
hyperinsulinismus.de

#hypoglycemia #clinicaltrials #raredisease

 Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer 

 Craig-Hallum bullish on Rezolute, initiates with a Buy 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858501/

Page 8

 Rezolute announces presentation of Phase 2 RIZE study sub-analyses 

 Rezolute management to meet with BTIG 

News

RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug - MSN

 Rezolute's chief medical officer buys shares worth over $29k By Investing.com 

Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment - MarketWatch

Manufacturing A mAb For Congenital Hyperinsulinism - BioProcess Online

 Rezolute's chief medical officer buys $18.8k in company stock 

FDA lifts partial clinical hold on phase 3 low blood sugar treatment - BioPharma-Reporter.com

Daron Evans, CFO of Rezolute, buys $53,166 in common shares - Investing.com

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) - GlobeNewswire

 Why Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday? 


                    Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update                

Today is World Neuroendocrine Cancer Day. Together, we can help support individuals impacted by neuroendocrine tumors (NETs), a group of rare cancers that develop in hormone-producing cells across the body, including the pancreas, and are frequently misdiagnosed. NETs, like many other tumors, can overproduce insulin or insulin-like substances, leading to tumor hyperinsulinism (HI) and severe hypoglycemia.

If left untreated, tumor HI can significantly impact quality of life and the ability to receive tumor-directed therapies. 

Learn the signs and symptoms of NETs to encourage earlier diagnosis and awareness: https://lnkd.in/gYuPmfcZ

Together, we can make a difference! 🦓 #NETCancerDay #RareDisease #CancerAwareness #letstalkaboutnets #cancer

Page 3

Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey

Rezolute

Business:

Drug notes:

About: